A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 73
- Registration Number
- NCT01929265
- Locations
- 🇮🇹
SC Ematologia - AO SS. Antonio e Biagio e C. Arrigo, Alessandria, AL, Italy
🇮🇹Divisione di Ematologia Ospedale Niguarda, Milano, MI, Italy
🇮🇹Centro Oncologico Modenese, Modena, MO, Italy
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 159
- Registration Number
- NCT01827605
- Locations
- 🇮🇹
IRCC Onco-Ematologia, Candiolo, Italy
🇮🇹Spedali Civili, Brescia, Italy
🇮🇹Emat Univ - Città della salute e della scienza di Torino, Torino, TO, Italy
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 20
- Registration Number
- NCT01822886
- Locations
- 🇮🇹
A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino, Torino, Italy
🇮🇹A.O. SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
🇮🇹Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola, Bologna, Italy
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
- Conditions
- Interventions
- First Posted Date
- 2013-03-06
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 108
- Registration Number
- NCT01805557
- Locations
- 🇮🇹
ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milano, MI, Italy
🇮🇹A.O. SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Ematologia, Meldola, Forlì-Cesena, Italy
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 42
- Registration Number
- NCT01737177
- Locations
- 🇮🇹
Centro di riferimento Oncologico CRO Aviano, Aviano, Pordenone, Italy
🇮🇹IRCCS-Centro di Riferimento Oncologico UO di Ematologia e Trapianto Cellule Staminali, Rionero in Vulture, Potenza, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST Meldola, Meldola, Forlì Cesena, Italy
Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL
- Conditions
- Interventions
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 57
- Registration Number
- NCT01662050
- Locations
- 🇮🇹
AOU Careggi, Firenze, FI, Italy
🇮🇹IRCCS Ospedale Oncologico, Bari, BA, Italy
🇮🇹Ospedale degli Infermi di Rimini, Rimini, RN, Italy
Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 35
- Registration Number
- NCT01523834
- Locations
- 🇮🇹
Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
🇮🇹Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola, Bologna, Italy
🇮🇹Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Italy
A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 50
- Registration Number
- NCT01523847
- Locations
- 🇮🇹
Policlinico S. Orsola Malpighi, Bologna, Italy
🇮🇹Ospedale Guglielmo da Saliceto, Piacenza, Italy
🇮🇹SC Medicina trasfusionale ed Ematologia Ospedale civile di Ivrea, Ivrea, Torino, Italy
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 76
- Registration Number
- NCT01523860
- Locations
- 🇮🇹
Oncologia Medica ed Ematologia, Istituto Clinica Humanitas, Rozzano, Milano, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Forlì-Cesena, Italy
🇮🇹UO Oncologia ed Onco-Ematologia, Ospedale di Rimini, Rimini, Rn, Italy
Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT
- Conditions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2013-03-06
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 495
- Registration Number
- NCT01478191
- Locations
- 🇮🇹
A.O. di Padova Divisione di Oncologia Medica, Padova, Italy
🇮🇹Divisione di Ematologia Osp.Businco, Cagliari, Italy
🇮🇹Istituto Oncologico del Mediterraneo, Catania, Italy